(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morgans presented an observational study characterizing treatment patterns and subsequent second-line therapy in both cisplatin-eligible and ineligible patients with aUC. In the past few years, programmed death 1/ligand 1 inhibitors (PD-1/L1i) have become recommended for first-line (1L) therapy in aUC patients who are cisplatin-ineligible and have high PD-L1 expression or who are ineligible for any platinum-containing chemotherapy regardless of PD-L1 status. However, current, real-world data on PD-1/L1i use in this setting are limited.